Skip to Content

Evolutionary Genomics Inc FNAM

Morningstar Rating
$0.45 −0.15 (25.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

FNAM is trading within a range we consider fairly valued.
Price
$0.45
Fair Value
$1.22
Uncertainty
Extreme
1-Star Price
$3.69
5-Star Price
$2.88
Economic Moat
Stcdcc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FNAM is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.60
Day Range
$0.450.45
52-Week Range
$0.450.72
Bid/Ask
$0.06 / $1.00
Market Cap
$2.99 Mil
Volume/Avg
355 / 1,261

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
4

Valuation

Metric
FNAM
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
FNAM
Quick Ratio
3.68
Current Ratio
3.92
Interest Coverage
Quick Ratio
FNAM

Profitability

Metric
FNAM
Return on Assets (Normalized)
−59.78%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
FNAM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBpn$546.8 Bil
VRTX
Vertex Pharmaceuticals IncPgwrwy$112.0 Bil
REGN
Regeneron Pharmaceuticals IncTjsdcz$108.6 Bil
MRNA
Moderna IncKdjj$35.9 Bil
ARGX
argenx SE ADRGznpg$24.1 Bil
BNTX
BioNTech SE ADRTxf$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncXxkkmt$20.0 Bil
BMRN
Biomarin Pharmaceutical IncPppnhn$17.0 Bil
RPRX
Royalty Pharma PLC Class ASvknmc$14.0 Bil
INCY
Incyte CorpSvlft$13.6 Bil

Sponsor Center